Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Añadir filtros








Intervalo de año
1.
Chinese Journal of Practical Internal Medicine ; (12): 977-980, 2019.
Artículo en Chino | WPRIM | ID: wpr-816138

RESUMEN

OBJECTIVE: To explore the relationship between chronic complications of type 2 diabetes mellitus(T2 DM)and obstructive sleep apnea syndrome(OSAS). METHODS: The data of 153 hospitalized T2 DM patients aged 40-65 years were collected; the demograhic data was recorded, biochemical indicators were recorded and analyzed, and the patients were screened for chronic complications of diabetes and OSAS. The patients with ketosis, acidosis and infection, and those who were addicted to alcohol,smoking or drug or with mental illness, or severe organ dysfunction were excluded.According to whether OSAS was combined, they were divided into the OSAS group and the control group were divided into groups. The differences in the incidence of chronic complications between the two groups were compared.Spearman correlation analysis was used to determine the relationship between chronic complications and OSAS.RESULTS: The incidence of diabetic peripheral neuropathy(DPN)in the OSAS group was higher than in the control group(45% vs. 26.9%, P=0.017). The incidence of coronary heart disease was significantly higher in the OSAS group than in the control group(20% vs. 8.6%, P=0.038). The differences were statistically significant.Spearman correlation analysis showed that OSAS was positively correlated with diabetic peripheral neuropathy(P=0.021)and coronary heart disease(P=0.041). CONCLUSION: OSAS may be associated with peripheral neuropathy and coronary heart disease in patients with T2 DM.

2.
China Journal of Chinese Materia Medica ; (24): 3509-3515, 2017.
Artículo en Chino | WPRIM | ID: wpr-335826

RESUMEN

Tobacco black shank is one of the most harmful soil-borne diseases infected by Phytophthora parasitica. In order to probe the control method to this disease, in this study, the mycelial growth rate method was employed to investigate the antifungal effects of extracts from stem-leaf and root, root exudates, and their combination of Scrophularia ningpoensis, Chuanmingshen violaceum and Pinellia ternata The results showed that: ①Stem-leaf and root extracts of S. ningpoensis, C. violaceum and P. ternata exhibited different antifungal activities, and the inhibition increased with the increase of extract concentration. The antifungal effect of S. ningpoensis extracts at 0.5 g•mL⁻¹ was the strongest than other medicinal plants, the inhibition rate of steam-leaf and root extracts reached 74.88%, 69.27%, respectively. The inhibitory effect of C. violaceum and P. ternata was relatively lower, however, there is a significant gain effect after combination of steam-leaf and root extracts of C. violaceum. ②The root exudates of S. ningpoensis, C. violaceum and P. ternata showed fungistasis to Phytophthora nicotianae, and fungistasis was enhanced with the increase of root exudate concentration. The antifungal effect in the order of C. violaceum > S. ningpoensis > P. ternata. ③The antifungal activity of combination of extract and root exudate from S. ningpoensis was similar with the effect of C. violaceum, they were both stronger than P. ternata, and the antifungal activity for three combination were located between the antifungal activity of their extracts and root exudates. S. ningpoensis and C. violaceum can be potentially applied to prevent and control the tobacco black shank.

3.
Journal of Experimental Hematology ; (6): 213-218, 2010.
Artículo en Chino | WPRIM | ID: wpr-328541

RESUMEN

The aim of this study was to explore the clinical efficiency and side effects of GHA-priming therapy on patients with acute monocytic leukemia, and to analyze its mechanism. 37 patients with refractory, relapse, hypocellular acute monocytic leukemia and elderly patients with AML-M(5) were treated with GHA-priming therapy (G-CSF, homoharringtonine and low dosage of cytarabine). Clinical efficiency, side effects, and therapy-relevant mortality were observed. By using U937 cell line as in vitro model, effect of G-CSF on cell cycle was determined by propidium iodide staining method. The inhibition rate, apoptosis rate of U937 cell line treated with various combination of G-CSF, homoharringtonine and cytarabine were detected by flow cytometry. The expression of MLAA34 on U937 before or after treating with chemotherapy was analyzed by immunohistochemical method. The results showed that in all the 37 patients, the total remission rate was 62.2% [complete remission rate was 45.95% (17/37) and partial remission rate was 16.2% (6/37)]. The incidence of granulocyte deficiency was 18.92% (2/37) with median time of 4 days. The severe infection occurred in 2 cases. No severe bleeding, no mild digestive effect occurred. Other non-hematological toxicities were low in vitro when incubated with G-CSF for 24 hours, the S-phase cells obviously increased. The inhibition rate, apoptosis rate and expression of MLAA34 of U937 cells treated by GHA significantly decreased as compared with cells treated with HA. It is concluded that the GHA priming therapy can be used to treat patients with refractory, relapse, senile and hypocellular acute monocytic leukemia with satisfied response rate and low hematological and non-hematological toxicities. G-CSF can enhance cytotoxicity of drugs such as Ara-C and HHT by promoting G(0) phase cells into the reproductive cycle. GHA and HA therapy can inhibit cell proliferation, induce apoptosis, and the former has a more significant function. GHA priming therapy can down regulate the expression of MLAA 34. MLAA-34 is a novel anti-apoptotic factor of acute monocytic leukemia.


Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Protocolos de Quimioterapia Combinada Antineoplásica , Usos Terapéuticos , Citarabina , Factor Estimulante de Colonias de Granulocitos , Usos Terapéuticos , Harringtoninas , Leucemia Monocítica Aguda , Quimioterapia , Resultado del Tratamiento , Células U937
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA